These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 38969530)

  • 1. Advancing Toward a Human Immunodeficiency Virus Cure: Initial Progress on a Difficult Path.
    Margolis DM
    Infect Dis Clin North Am; 2024 Sep; 38(3):487-497. PubMed ID: 38969530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curing HIV: Seeking to Target and Clear Persistent Infection.
    Margolis DM; Archin NM; Cohen MS; Eron JJ; Ferrari G; Garcia JV; Gay CL; Goonetilleke N; Joseph SB; Swanstrom R; Turner AW; Wahl A
    Cell; 2020 Apr; 181(1):189-206. PubMed ID: 32220311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Latency reversal and viral clearance to cure HIV-1.
    Margolis DM; Garcia JV; Hazuda DJ; Haynes BF
    Science; 2016 Jul; 353(6297):aaf6517. PubMed ID: 27463679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Reservoirs During Suppressive Therapy.
    Barton K; Winckelmann A; Palmer S
    Trends Microbiol; 2016 May; 24(5):345-355. PubMed ID: 26875617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques.
    Dashti A; Waller C; Mavigner M; Schoof N; Bar KJ; Shaw GM; Vanderford TH; Liang S; Lifson JD; Dunham RM; Ferrari G; Tuyishime M; Lam CK; Nordstrom JL; Margolis DM; Silvestri G; Chahroudi A
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32817214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review of Current Strategies Towards the Elimination of Latent HIV-1 and Subsequent HIV-1 Cure.
    Maina EK; Adan AA; Mureithi H; Muriuki J; Lwembe RM
    Curr HIV Res; 2021; 19(1):14-26. PubMed ID: 32819259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for treatment of latent HIV.
    Barton KM; Burch BD; Soriano-Sarabia N; Margolis DM
    Clin Pharmacol Ther; 2013 Jan; 93(1):46-56. PubMed ID: 23212106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.
    Margolis DM; Archin NM
    J Infect Dis; 2017 Mar; 215(suppl_3):S111-S118. PubMed ID: 28520964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding a cure for human immunodeficiency virus-1 infection.
    Blankson JN; Siliciano JD; Siliciano RF
    Infect Dis Clin North Am; 2014 Dec; 28(4):633-50. PubMed ID: 25277513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Immunodeficiency Virus 1 (HIV-1): Viral Latency, the Reservoir, and the Cure.
    Ventura JD
    Yale J Biol Med; 2020 Sep; 93(4):549-560. PubMed ID: 33005119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges and Promise of Human Immunodeficiency Virus Remission.
    Li Y; Mohammadi A; Li JZ
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):4-12. PubMed ID: 33586773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
    Chou TC; Maggirwar NS; Marsden MD
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Latent Reservoir for HIV-1.
    Sengupta S; Siliciano RF
    Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic regulation of HIV-1 persistence and evolving strategies for virus eradication.
    Dhamija N; Rawat P; Mitra D
    Subcell Biochem; 2013; 61():479-505. PubMed ID: 23150264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Residual Proviral Reservoirs: A High Risk for HIV Persistence and Driving Forces for Viral Rebound after Analytical Treatment Interruption.
    Wang X; Xu H
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33670027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current views on HIV-1 latency, persistence, and cure.
    Melkova Z; Shankaran P; Madlenakova M; Bodor J
    Folia Microbiol (Praha); 2017 Jan; 62(1):73-87. PubMed ID: 27709447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
    Darcis G; Berkhout B; Pasternak AO
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutics for HIV-1 reactivation from latency.
    Sgarbanti M; Battistini A
    Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.